Search clinical trials for: SHR7280

Total 54 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

Endometriosis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

Uterine Fibroids With Menorrhagia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Trial of SHR2285 in Healthy Subjects

Healthy Volunteers

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

Thrombosis

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Thrombosis

China
Peking University Cancer Hospital & Institute

Recruiting

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

Thrombus

China
Spero Therapeutics

Recruiting

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Spero Therapeutics

Completed

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

Healthy Volunteer

United States
Spero Therapeutics
Simbec Research

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Henan Cancer Hospital

Active, not recruiting

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Gastric Cancer

China
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Spero Therapeutics

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Mycobacterium Avium Complex | Non-tuberculous Mycobacterium Pulmonary Disease

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

Prevention of Venous Thrombosis After TKA

China
Yanqiao Zhang
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (HZ-T-PD1-APA)

Hepatocellular Carcinoma
Spero Therapeutics

Completed

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Healthy Volunteers

United States
Peking University

Unknown

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NK/T-cell Lymphoma
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Prostate Cancer | Hormone-Dependent Prostate Cancer

China, Czechia, Poland, Bulgaria
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

Thrombosis

China
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
Sun Yat-sen University

Recruiting

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Persistent Cervical Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Drug-drug Interaction,SHR3680

China

3

Subscribe